Date: 2013-04-12
Type of information: Private placement
Company: Genfit (France)
Investors:
Amount: € 14.325 million
Funding type: private placement
Planned used: The funds raised will be used by Genfit to pursue the development of its most advanced drug candidate, GFT505, in phase IIb, in order to maximize its value in preparation of out-licencing the commercial rights before the start of phase III and to allow the rapid advancement of other programs in its pipeline, namely the development of compounds in preclinical phase, discovered in the programs TGFTX1 and TGFTX3 for partnership alliances.
Others:
Genfit, a biopharmaceutical company focusing on the early diagnosis and preventive treatment of cardiometabolic and associated disorders, has announced the launch of a capital increase through issuance of ordinary shares without preferential subscription rights by way of a private placement offered exclusively to qualified French and Foreign investors. The gross amount of this capital increase is expected to be between 12 and 15 million euros subject the limits stipulated by the 17 th resolution of the company’s combined Shareholders’ Meeting held on 26th of June 2012, which approved the issuance of up to 2.933.800 shares and representating a maximum of 20 % of the capital.
Therapeutic area: Cardiovascular diseases - Metabolic diseases - Liver diseases
